Both Nreu et al. (39), Monami et al. (40) found that the incidence of pancreatitis and pancreatic cancer with GLP-1 RAs including semaglutide was not significant from that observed in comparator arms. This evidence concerns the gene GLP1R and familial pancreatic carcinoma.